Saskatchewan River Sturgeon Management Board

EQS-News: Wolford AG: Management Board welcomes resolved capital increase

Retrieved on: 
Thursday, December 1, 2022

Bregenz, December 1, 2022: The Extraordinary General Meeting of Wolford AG today voted in favor of a capital reduction and a subsequent capital increase.

Key Points: 
  • Bregenz, December 1, 2022: The Extraordinary General Meeting of Wolford AG today voted in favor of a capital reduction and a subsequent capital increase.
  • The capital increase is to be implemented in the first quarter of 2023.
  • Upon implementation of the capital increase, the Company will receive up to 20,157,450.00 euros.
  • "Wolford AG will receive up to EUR 20.2 million as part of these capital measures, which will increase the equity ratio to around 10 percent.

EQS-News: Mutares has successfully completed the acquisition of Heat Transfer Technology (NEM Energy) from Siemens Energy B.V.

Retrieved on: 
Thursday, December 1, 2022

Mutares has successfully completed the acquisition of Heat Transfer Technology (NEM Energy) from Siemens Energy B.V.

Key Points: 
  • Mutares has successfully completed the acquisition of Heat Transfer Technology (NEM Energy) from Siemens Energy B.V.
  • Mutares has successfully completed the acquisition of Heat Transfer Technology (NEM Energy) from Siemens Energy B.V.
    Munich, Amsterdam, 1 December 2022 Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully completed the acquisition of Heat Transfer Technology from Siemens Energy B.V.
  • This new platform investment is strengthening the Engineering & Technology segment and will operate under the name NEM Energy B.V.
  • The exhaust and diverter solutions business is located in Recklinghausen, Germany, and is an integral part of NEM Energy B.V.

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

Retrieved on: 
Wednesday, November 30, 2022

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.

Key Points: 
  • The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvus STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.
  • BioNTech has the option to license global development and commercialization rights to these programs at the development candidate stage.
  • The collaboration with Ryvu provides us with the opportunity to complement our immunotherapy pipeline with a portfolio of potent immunomodulatory molecules.
  • BioNTech will fund all discovery, research and development activities, including Ryvus discovery and research activities under the multi-target research collaboration.

EQS-News: CHEPLAPHARM remains on growth track

Retrieved on: 
Tuesday, November 29, 2022

CHEPLAPHARM AG, a leading international platform for well-established branded medicines, remains on growth track.

Key Points: 
  • CHEPLAPHARM AG, a leading international platform for well-established branded medicines, remains on growth track.
  • After achieving the highest revenue in the Company's history in financial year 2021 with 1.1bn, CHEPLAPHARM continued its revenue and earnings growth in the first nine months of financial year 2022.
  • CHEPLAPHARM increased revenue by 21% year-over-year to 957m in the first three quarters of 2022 (9M2021: 793m).
  • In October 2022, two leading global investors invested growth capital totaling 550m in CHEPLAPHARM, strengthening and diversifying the Company's financial base.

NORNICKEL HAS DEVELOPED LONG-TERM SCENARIOS FOR GLOBAL ECONOMY AND CLIMATE CHANGE

Retrieved on: 
Sunday, November 27, 2022

The Company will use these scenarios for strategic planning, to assess risks and identify opportunities emerging from the global energy transition, and to adopt to climate change.

Key Points: 
  • The Company will use these scenarios for strategic planning, to assess risks and identify opportunities emerging from the global energy transition, and to adopt to climate change.
  • Vladimir Zhukov, Nornickel Vice President, Investor Relations and Sustainable Development commented: The climate change agenda remains highly relevant to us.
  • Using the long-term climate and social and economic scenarios for the global economy is key to adapting to the physical risks of climate change, as well as risks associated with the global energy transition.
  • The Company drafted three long-term social and economic scenarios for the global economy and respective climate change scenarios, which were labelled as Rapid Transformation, Sustainable Palladium and Global Growth.

EQS-News: Antibacterial silver coating technology: acceleration of human clinical trial through successfully implemented clinical trial protocol changes

Retrieved on: 
Sunday, November 27, 2022

aap Implantate AG ("aap" or the "Company") announces that with the recent approval for an amendment to the clinical trial plan by the BfArM and the Ethics Committee, an important step towards accelerating the human clinical trial of the antibacterial silver coating technology developed by aap could be implemented.

Key Points: 
  • aap Implantate AG ("aap" or the "Company") announces that with the recent approval for an amendment to the clinical trial plan by the BfArM and the Ethics Committee, an important step towards accelerating the human clinical trial of the antibacterial silver coating technology developed by aap could be implemented.
  • Based on the changes to the clinical trial plan, aap plans to complete the number of patients to be included under the human clinical trial in mid-2024, after which the mandatory follow-up year will begin.
  • With its antibacterial silver coating technology, aap is addressing one of the greatest and yet inadequately solved challenges in traumatology: the reduction of Surgical Site Infections (SSI).
  • In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants.

EQS-News: USU Software AG: USU achieves further record quarter and specifies guidance for 2022

Retrieved on: 
Sunday, November 27, 2022

Following on from the successful first half of the year, USU Software and its subsidiaries (hereinafter also referred to as the USU Group or USU) further accelerated their growth momentum in the third quarter of 2022.

Key Points: 
  • Following on from the successful first half of the year, USU Software and its subsidiaries (hereinafter also referred to as the USU Group or USU) further accelerated their growth momentum in the third quarter of 2022.
  • USU thus increased its consolidated sales by 16.6% year-on-year to EUR32.6 million in the third quarter of 2022 (Q3 2021: EUR27.9 million).
  • License revenue saw above-average growth of 32.6% to EUR 4.0 million in the third quarter of 2022 (Q3 2021: EUR 3.0 million).
  • At the same time, SaaS sales enjoyed even stronger growth of 35.6% year-on-year to EUR 3.7 million in Q3 2022 (Q3 2021: EUR 2.8 million).

EQS-News: Gigaset AG publishes report on third quarter and first nine months of 2022: Phones with plus 2.3%, Professional with plus 8.8% increase on a nine-month view

Retrieved on: 
Sunday, November 27, 2022

Bocholt, November 22nd, 2022 - Gigaset AG (ISIN: DE0005156004), an international communications technology company, today published its report for the third quarter and the first nine months of 2022.

Key Points: 
  • Bocholt, November 22nd, 2022 - Gigaset AG (ISIN: DE0005156004), an international communications technology company, today published its report for the third quarter and the first nine months of 2022.
  • Earnings before interest and taxes (EBIT) declined to EUR -2.2 million in the third quarter (Q3 2021: EUR 3.3 million).
  • "We are facing a new reality in logistics and material availability," said Thomas Schuchardt, CFO of Gigaset AG.
  • "Accordingly, procurement and supply chain issues weighed on our results in the first nine months of the year.

EQS-News: NFON AG forges ahead with realignment as a provider of integrated business communications in the third quarter of 2022

Retrieved on: 
Sunday, November 27, 2022

Munich, 17 November 2022 NFON, a European provider of integrated business communication from the cloud, continued to expand its business activities in the first three quarters of 2022 and achieved key strategic milestones.

Key Points: 
  • Munich, 17 November 2022 NFON, a European provider of integrated business communication from the cloud, continued to expand its business activities in the first three quarters of 2022 and achieved key strategic milestones.
  • In doing so, the company laid the foundation for further growth as a provider of integrated business communications in the years ahead.
  • Company managers are increasingly implementing holistic, enterprise-wide cloud strategies that result in high demand for integrated business communications.
  • The quarterly report is available for download starting today on the NFON AG website in the Investor Relations section.

EQS-News: Cannovum AG expands management board

Retrieved on: 
Sunday, November 27, 2022

Berlin, 25.11.2022 - Cannovum AG (stock exchanges Dsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) expands its Management Board.

Key Points: 
  • Berlin, 25.11.2022 - Cannovum AG (stock exchanges Dsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) expands its Management Board.
  • The long-time journalist and communications expert has been Chief Marketing Officer (CMO) for Cannovum AG since September 2022.
  • "We are very pleased to have Klaus Madzia, an experienced media and marketing professional, on the board," says Pia Marten, board member and co-founder of Cannovum AG.
  • Cannovum AG stands ready to become a major player in this emerging segment."